Posterior reversible encephalopathy syndrome features reversible cortical neurologic dysfunction and characteristic findings on brain imaging studies. This syndrome can be caused by several agents including traditional chemotherapy and immunosuppressive drugs. Targeted therapies such as agents binding vascular endothelial growth factor/VEGFR, CD20 and cytotoxic T-cell lymphocyte antigen 4 (CTLA-4) antigens are also among the culprits. Vemurafenib is a BRAF gene inhibitor that has not been previously linked with posterior reversible encephalopathy syndrome. We report herein the first such case and believe that further studies confirming this association are warranted. We further review the existing posterior reversible encephalopathy syndrome cases associated with targeted therapies in the scientific literature.
JangS1AtkinsMB. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies. Clin Pharmacol Ther2013; 95: 24–31.
13.
TajimaYIsonishiKKashiwabaT. Two similar cases of encephalopathy, possibly a reversible posterior leukoencephalopathy syndrome: serial findings of magnetic resonance imaging, SPECT, and angiography. Intern Med1999; 38: 54–58.
14.
EdvinssonLOmanCSjobergN. Autonomic nerves, mast cells, and amine receptors in human brain vessels. Brain Res1976; 15: 377–393.
15.
ScappaticciFASkillingsJRHoldenSR. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst2007; 99: 1232–1239.
16.
GluskerPRechtLLaneB. Reversible posterior encephalopathy syndrome and bevacizumab. N Engl J Med2006; 354: 980–982.
17.
AllenJAdlakhaABergethonP. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol2006; 63: 1475–1478.
KoopmanMMullerEWPuntCJ. Reversible posterior leukoencephalopathy syndrome caused by bevacizumab: report of a case. Dis Colon Rectum2008; 51: 1425–1426.
23.
LevyCFOoKZFiremanF. Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab. Pediatr Blood Cancer2009; 52: 669–671.
24.
LauPPaunipagarB. Posterior reversible encephalopathy syndrome with bevacizumab. Hong Kong Med J2011; 17: 80–81.
25.
ChangYMbeoGLittmanSJ. Reversible posterior leukoencephalopathy syndrome associated with concurrent bevacizumab, gemcitabine, and oxaliplatin for cholangiocarcinoma. J Gastrointest Cancer2012; 43: 505–507.
26.
SeetRCRabinsteinAA. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. QJM2012; 105: 69–75.
27.
LouETurnerSSumrallA. Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. J Clin Oncol2011; 29: e739–e742.
28.
SclafaniFGiuseppeGMezynksiJ. Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer. J Clin Oncol2012; 30: e257–e259.
29.
LazarusMAmundsonSBelaniR. An association between bevacizumab and recurrent posterior reversible encephalopathy syndrome in a patient presenting with deep vein thrombosis: a case report and review of the literature. Case Rep Oncol Med2012; 2012: 819546–819546.
30.
DerschRStichOGollerK. Atypical posterior reversible encephalopathy syndrome associated with chemotherapy with Bevacizumab, Gemcitabine and Cisplatin. J Neurol2013; 260: 1406–1407.
31.
HaefnerMDSicilianoRDWidmerLA. Reversible posterior leukoencephalopathy syndrome after treatment of diffuse large B-cell lymphoma. Onkologie2007; 30: 138–140.
32.
HosoiMYamamotoGImaiY. Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma. Ann Hematol2010; 89: 207–208.
33.
ZitoJALeeCCJohnsonS. Reversible posterior leukoencephalopathy syndrome after rituximab. Am J Emerg Med2010; 28: 537.e1-e2–537.e1-e2.
34.
SiddiqiAI. Rituximab as a possible cause of posterior reversible encephalopathy syndrome. Australas Med J2011; 4: 513–515.
35.
MizutaniMNakamoriYSakaguchiH. Development of syndrome of inappropriate secretion of ADH and reversible posterior leukoencephalopathy during initial rituximab-CHOP therapy in a patient with diffuse large B-cell lymphoma. Rinsho Ketsueki2013; 54: 269–272.
36.
DoganEAksoySArslanC. Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. Med Oncol2010; 27: 1436–1437.
37.
MedioniJCojocarasuOBanuE. Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient. Targ Oncol2007; 2: 193–195.
38.
KapiteijnEBrandAKroepJ. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol2007; 18: 1745–1747.
ChenAAgarwalN. Reversible posterior leucoencephalopathy syndrome associated with sunitinib. Intern Med J2009; 39: 341–342.
41.
PadhyBMShanmugamSPGuptaYK. Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy. Br J Clin Pharmacol2011; 71: 777–779.
42.
HadjJOBravenRDTillierC. Reversible posterior leukoencephalopathy syndrome during sunitinib therapy for metastatic renal cell carcinoma. J Oncol Lett2012; 3: 1293–1296.
43.
KhanKHFentonAMurtaghE. Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature. Tumori2012; 98: 139e–142e.
AsaithambiGPetersBRHurlimanE. Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma. J Clin Pharm Ther2013; 38: 175–176.
46.
FoersterRWelzelTDebusJ. Posterior reversible encephalopathy syndrome associated with pazopanib. Case Rep Oncol2013; 6: 204–208.
47.
MaurM1TomaselloCFrassoldatiA. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol2012; 30: e76–e78.
48.
LanctôtKLNaranjoCA. Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Clin Pharmacol Ther1995; 58: 692–698.
